CUSIP
No. Not
Applicable.
|
1
|
Name
of Reporting Person: Michael
S. Weiss
I.R.S.
Identification No. of Above Person (Entities Only):
|
||
2
|
Check
the Appropriate Box if a Member of a Group
(a)
(b)
|
||
3
|
SEC
Use Only
|
||
4
|
Source
of Funds
OO
|
||
5
|
Check
box if disclosure of legal proceedings is required pursuant to
items 2(d)
or 2(e)
|
||
6
|
Citizenship
or Place of Organization
United
States
|
NUMBER
OF
SHARES
BENEFICIALLY
OWNED
BY
EACH
REPORTING
PERSON
WITH
|
7
|
Sole
Voting Power:
4,713,635
|
|
8
|
Shared
Voting Power: -
0 -
|
||
9
|
Sole
Dispositive Power:
4,713,635
|
||
10
|
Shared
Dispositive Power: -
0 -
|
11
|
Aggregate
Amount Beneficially Owned by Each Reporting Person: 4,713,635
|
||
12
|
Check
Box if the Aggregate Amount in Row (9) Excludes Certain Shares
|
||
13
|
Percent
of Class Represented by Amount in Row (9): 10.8%
|
||
14
|
Type
of Reporting Person:
IN
|
(a) |
The
Reporting Person filing this statement is Michael S. Weiss, a natural
person.
|
(b) |
The
address of Mr. Weiss’s principal business office is Keryx
Biopharmaceuticals, Inc., 750 Lexington Avenue, New York, New York
10022.
|
(c) |
Mr.
Weiss is the Chairman and Chief Executive Officer of Keryx.
|
(d) |
Mr.
Weiss has not, during the past five years, been convicted in a criminal
proceeding (excluding traffic violations or similar misdemeanors).
|
(e) |
Mr.
Weiss has not, during the past five years, been party to a civil
proceeding of a judicial or administrative body of competent jurisdiction
and as a result of such proceeding, was or is subject to a judgment,
decree or final order enjoining future violations of, or prohibiting
or
mandating activities subject to, federal or state securities laws
or
finding any violation with respect to such laws.
|
(f) |
Mr.
Weiss is a United States citizen.
|
(a) |
Mr.
Weiss may be deemed to be the beneficial owner of 4,713,635 shares
of
Common Stock. Such shares constitute approximately 10.8% of the issued
and
outstanding shares of Common Stock. As of March 5, 2007, there were
43,497,781 shares of Common Stock outstanding. Included in Mr. Weiss’
percentage of beneficial ownership are shares underlying options
beneficially owned by Mr. Weiss that will vest within 60 days of
March 5,
2007. Options or warrants held by other stockholders that are not
attributed to Mr. Weiss were disregarded in this calculation. Beneficial
ownership is determined in accordance with the rules of the Securities
and
Exchange Commission and includes voting or investment power with
respect
to the shares of Common Stock.
|
(b) |
Mr.
Weiss has sole voting power and investment power for the Common Stock
and
Options, except to the extent authority is shared by spouses under
communist property laws.
|
(c) |
Mr.
Weiss has not effected any transaction relating to Common Stock during
the
past 60 days.
|
(d) |
To
Mr. Weiss’ knowledge, no other person has the right to receive or the
power to direct the receipt of dividends from, or proceeds from the
sale
of, the Common Stock.
|
(e) |
Not
applicable.
|
Date: March 7, 2007 | KERYX BIOPHARMACEUTICALS, INC. | |
By: | /s/ Michael S. Weiss | |
Name: | Michael S. Weiss | |
Title: | Chairman and Chief Executive Officer | |